JP2007502792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502792A5 JP2007502792A5 JP2006523585A JP2006523585A JP2007502792A5 JP 2007502792 A5 JP2007502792 A5 JP 2007502792A5 JP 2006523585 A JP2006523585 A JP 2006523585A JP 2006523585 A JP2006523585 A JP 2006523585A JP 2007502792 A5 JP2007502792 A5 JP 2007502792A5
- Authority
- JP
- Japan
- Prior art keywords
- active substance
- molar ratio
- organic
- water
- aqueous solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013543 active substance Substances 0.000 claims 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 10
- 239000000843 powder Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- 239000003125 aqueous solvent Substances 0.000 claims 6
- 238000001035 drying Methods 0.000 claims 5
- 239000010419 fine particle Substances 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 239000003595 mist Substances 0.000 claims 4
- 239000007921 spray Substances 0.000 claims 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- 125000000240 D-tyrosyl group Chemical group N[C@@H](C(=O)*)CC1=CC=C(C=C1)O 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000013022 formulation composition Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10338403.0 | 2003-08-18 | ||
| DE10338403A DE10338403A1 (de) | 2003-08-18 | 2003-08-18 | Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
| PCT/EP2004/009103 WO2005018614A1 (de) | 2003-08-18 | 2004-08-13 | Pulverformulierung, enthaltend den cgrp-antagonisten 1- (n2-(3,5-dibrom-n-(4-(3,4-dihydro-2(1h)-oxochinazolin-3-yl)- 1-piperidinyl)carbonyl)-d-tyrosyl)-l-lysyl)-4-(4-pyridinyl)-piperazin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007502792A JP2007502792A (ja) | 2007-02-15 |
| JP2007502792A6 JP2007502792A6 (ja) | 2007-05-10 |
| JP2007502792A5 true JP2007502792A5 (https=) | 2007-09-27 |
Family
ID=34201782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523585A Pending JP2007502792A (ja) | 2003-08-18 | 2004-08-13 | Ｃｇｒｐアンタゴニスト１−［ｎ２−［３，５−ジブロモ−ｎ−［［４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル］カルボニル］−ｄ−チロシル］−ｌ−リシル］−４−（４−ピリジニル）−ピペラジンを含有する粉末製剤、その吸入粉末としての製造方法及び使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1660046A1 (https=) |
| JP (1) | JP2007502792A (https=) |
| AR (1) | AR045461A1 (https=) |
| CA (1) | CA2536053A1 (https=) |
| DE (1) | DE10338403A1 (https=) |
| TW (1) | TW200516077A (https=) |
| WO (1) | WO2005018614A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10338402A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
| DE10338407A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin |
| DE10338399A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver |
| GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1242211A (en) * | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
| MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
| DE10139410A1 (de) * | 2001-08-17 | 2003-02-27 | Boehringer Ingelheim Pharma | Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
| DE10206770A1 (de) * | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096 |
| DE10207026A1 (de) * | 2002-02-20 | 2003-08-28 | Boehringer Ingelheim Kg | Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung |
-
2003
- 2003-08-18 DE DE10338403A patent/DE10338403A1/de not_active Withdrawn
-
2004
- 2004-08-13 EP EP04764097A patent/EP1660046A1/de not_active Withdrawn
- 2004-08-13 WO PCT/EP2004/009103 patent/WO2005018614A1/de not_active Ceased
- 2004-08-13 JP JP2006523585A patent/JP2007502792A/ja active Pending
- 2004-08-13 CA CA002536053A patent/CA2536053A1/en not_active Abandoned
- 2004-08-17 TW TW093124725A patent/TW200516077A/zh unknown
- 2004-08-18 AR ARP040102955A patent/AR045461A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Santos et al. | Spray drying: an overview | |
| Son et al. | Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: Effect of spray drying process conditions on aerosol performance | |
| JP2002531487A (ja) | 粉末の改良 | |
| Adi et al. | Effects of mechanical impaction on aerosol performance of particles with different surface roughness | |
| JP2012509922A5 (https=) | ||
| WO2021230340A1 (ja) | 新規吸入剤 | |
| TW200400184A (en) | Process for the preparation of an inhalation powder containing a salt of the CGRP antagonist BIBN4096 | |
| Rita Patrizia et al. | Nanospray drying as a novel technique for the manufacturing of inhalable NSAID powders | |
| CN104203918B (zh) | 作为β2肾上腺素受体激动剂的5‑(2‑{[6‑(2,2‑二氟‑2‑苯乙氧基)己基]氨基}‑1‑(R)‑羟乙基)‑8‑羟基喹啉‑2(1H)‑酮,半萘二磺酸盐的新的多晶型 | |
| JP2007502792A5 (https=) | ||
| AU2020292266A1 (en) | Carrier-based formulations and related methods | |
| Hamedani et al. | A novel particle engineering method for the production of inhalable cromolyn sodium powders by a combination of spray drier and nebulizer | |
| US20040014679A1 (en) | Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof | |
| CN113768910A (zh) | 包含富马酸福莫特罗吸入溶液的药物组件及其用途 | |
| CN101889994A (zh) | 一种硫酸沙丁胺醇缓释型吸入粉雾剂及其制备方法 | |
| JP2007502790A5 (https=) | ||
| JP4085063B2 (ja) | Ｃｇｒｐ拮抗剤ｂｉｂｎ４０９６を含有する吸入粉末及びその調製方法 | |
| JP2007502792A (ja) | Ｃｇｒｐアンタゴニスト１−［ｎ２−［３，５−ジブロモ−ｎ−［［４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル］カルボニル］−ｄ−チロシル］−ｌ−リシル］−４−（４−ピリジニル）−ピペラジンを含有する粉末製剤、その吸入粉末としての製造方法及び使用 | |
| JP2007502792A6 (ja) | Ｃｇｒｐアンタゴニスト１−［ｎ２−［３，５−ジブロモ−ｎ−［［４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル］カルボニル］−ｄ−チロシル］−ｌ−リシル］−４−（４−ピリジニル）−ピペラジンを含有する粉末製剤、その吸入粉末としての製造方法及び使用 | |
| JP2007502790A6 (ja) | Ｃｇｒｐアンタゴニスト１−〔ｎ２−〔３，５−ジブロモ−ｎ−〔〔４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル〕カルボニル〕−ｄ−チロシル〕−ｌ−リシル〕−４−（４−ピリジニル）−ピペラジンを含む微粒子、その調製方法及び吸入粉末としてのその使用 | |
| JP2007502790A (ja) | Ｃｇｒｐアンタゴニスト１−〔ｎ２−〔３，５−ジブロモ−ｎ−〔〔４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル〕カルボニル〕−ｄ−チロシル〕−ｌ−リシル〕−４−（４−ピリジニル）−ピペラジンを含む微粒子、その調製方法及び吸入粉末としてのその使用 | |
| CN119185259A (zh) | 一种西维来司他钠吸入组合物、药物组件及其应用 | |
| EP2340817A1 (en) | Drug carrier manufacturing method | |
| CN120919088A (zh) | 一种吲哚美辛可吸入干粒子及其制备方法和应用 | |
| JP2023529411A (ja) | アナタビン粉末組成物 |